Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)

2.12
Delayed Data
As of Feb 16
 -0.08 / -3.64%
Today’s Change
2.10
Today|||52-Week Range
9.93
-66.35%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$109.4M

Company Description

Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel antibiotics for serious and life-threatening bacterial infections. It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.

Contact Information

Tetraphase Pharmaceuticals, Inc.
480 Arsenal Street
Watertown Massachusetts 02472
P:(617) 715-3600
Investor Relations:
(617) 600-7040

Employees

Shareholders

Other institutional31.48%
Mutual fund holders28.90%
Individual stakeholders22.20%

Top Executives

Guy MacDonaldPresident, Chief Executive Officer & Director
Kamalam UnninayarChief Financial Officer
Larry TsaiChief Medical Officer
Jacques DumasChief Scientific Officer
Maria D. StahlSenior Vice President & General Counsel